Last $4.40 USD
Change Today -0.05 / -1.12%
Volume 6.4K
BIOC On Other Exchanges
As of 8:10 PM 08/22/14 All times are local (Market data is delayed by at least 15 minutes).

biocept inc (BIOC) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/5/14 - $10.02
52 Week Low
04/21/14 - $4.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOCEPT INC (BIOC)

Related News

No related news articles were found.

biocept inc (BIOC) Related Businessweek News

No Related Businessweek News Found

biocept inc (BIOC) Details

Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company’s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company is also developing other OncoCEE CTC tests, including OncoCEE-LU for lung cancer; OncoCEE-GA for gastric cancer; OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma. Biocept, Inc. sells its products through its direct sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States, as well as biopharma companies. The company was founded in 1997 and is headquartered in San Diego, California.

27 Employees
Last Reported Date: 03/28/14
Founded in 1997

biocept inc (BIOC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $66.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $227.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $208.2K
Compensation as of Fiscal Year 2013.

biocept inc (BIOC) Key Developments

Biocept, Inc. Announces Resignation of Farideh Z. Bischoff as Vice-President Translational Research and Clinical Development

On July 21, 2014, Farideh Z. Bischoff, Ph.D., notified the company of her intent to resign as Vice-President Translational Research and Clinical Development of Biocept, Inc., to be effective on August 12, 2014.

Biocept, Inc. Closes $10 Million Term Loan Facility with Oxford Finance LLC

Biocept, Inc. announced that it has closed a loan facility of up to $10 million with Oxford Finance LLC. The facility will support working capital and general corporate needs and augments the company's financial flexibility to pursue growth opportunities. The initial $5 million secured term loan, which Oxford funded on April 30, 2014, matures in July 2018 and bears interest at an annual floating rate of LIBOR plus 7.71%, with a 7.95% floor. Biocept may draw down the additional $5 million available under the facility upon achieving a revenue milestone by the end of November 2015. The initial term loan includes an interest-only period through July 2015, which can be extended through January 2016 upon Biocept's achievement of the same revenue milestone. The second term loan, if funded, shall have a conterminous interest-only period and maturity date with the first term loan.

Biocept, Inc., Annual General Meeting, Jun 12, 2014

Biocept, Inc., Annual General Meeting, Jun 12, 2014., at 10:00 Pacific Standard Time. Location: 5810 Nancy Ridge Drive. Agenda: To elect two Class I directors for a three-year term to expire at the 2017 annual meeting of stockholders; to ratify the appointment of Mayer Hoffman McCann P.C. as its independent registered public accounting firm for the fiscal year ending December 31, 2014; and to transact any other business that may be properly brought before the Annual Meeting or any continuation, adjournment or postponement thereof.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $4.40 USD -0.05

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.85 USD 0.00
BioMerieux €77.86 EUR -0.39
Daiichi Sankyo Co Ltd ¥1,865 JPY -1.00
Fluidigm Corp $26.12 USD -0.17
Illumina Inc $172.00 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 201.6x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at